![PCE artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts124/v4/94/32/1a/94321aaa-4adf-3df2-4810-f996719b6b1e/mza_11695467358112480520.jpg/100x100bb.jpg)
Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 2
PCE
English - March 21, 2022 16:00 - 24 minutes - 22.1 MB - ★★★★ - 6 ratingsCourses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Joleen Hubbard MD
Cathy Eng, MD
Stephanie Andrews, MS, APRN-C
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.